What to watch with CYP1A2 and longevity?

CYP1A2 is an enzyme primarily known for metabolizing caffeine and certain drugs. Regarding longevity, there is no strong direct evidence. Some studies suggest a link between CYP1A2 variants and cardiovascular risk – especially with high caffeine intake. Slow metabolizers (carriers of the *1F variant) may have a slightly increased risk of hypertension or heart attack when consuming large amounts of caffeine, which could indirectly affect lifespan. However, effect sizes are small and the evidence is mixed. MyBody-X does not test CYP1A2; its focus is nutrition and longevity, not pharmacogenetics. If you want to understand your caffeine metabolism, clinical genetic testing is needed. For longevity, lifestyle factors like sleep, exercise, and a balanced diet are far more important than single gene variants. The evidence is mechanistic and insufficient for actionable recommendations.